JP2004537517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537517A5 JP2004537517A5 JP2002589500A JP2002589500A JP2004537517A5 JP 2004537517 A5 JP2004537517 A5 JP 2004537517A5 JP 2002589500 A JP2002589500 A JP 2002589500A JP 2002589500 A JP2002589500 A JP 2002589500A JP 2004537517 A5 JP2004537517 A5 JP 2004537517A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- myc
- oligomer
- antisense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 16
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims 14
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims 14
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims 14
- 230000000692 anti-sense effect Effects 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 9
- 229940127089 cytotoxic agent Drugs 0.000 claims 9
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 108091027305 Heteroduplex Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 125000005309 thioalkoxy group Chemical group 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29172701P | 2001-05-17 | 2001-05-17 | |
| PCT/US2002/015842 WO2002092617A1 (en) | 2001-05-17 | 2002-05-17 | Combined approach to treatment of cancer using a c-myc antisense oligomer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004537517A JP2004537517A (ja) | 2004-12-16 |
| JP2004537517A5 true JP2004537517A5 (enExample) | 2005-07-28 |
Family
ID=23121574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002589500A Pending JP2004537517A (ja) | 2001-05-17 | 2002-05-17 | ｃ−ｍｙｃアンチセンスオリゴマーを使用した、癌を処置するための併用アプローチ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20030087861A1 (enExample) |
| EP (1) | EP1399462A4 (enExample) |
| JP (1) | JP2004537517A (enExample) |
| KR (1) | KR20040004629A (enExample) |
| CN (1) | CN1509292A (enExample) |
| CA (1) | CA2447052A1 (enExample) |
| NZ (1) | NZ530101A (enExample) |
| WO (1) | WO2002092617A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7640582B2 (en) | 2003-04-16 | 2009-12-29 | Silicon Graphics International | Clustered filesystem for mix of trusted and untrusted nodes |
| AU2004235396B2 (en) * | 2003-04-29 | 2010-11-25 | Sarepta Therapeutics, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
| US20050288246A1 (en) * | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
| US8815599B2 (en) | 2004-06-01 | 2014-08-26 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
| US20060122140A1 (en) * | 2004-11-22 | 2006-06-08 | Wang Jui H | In Vitro and in vivo silencing of human c-myc oncogene expression by poly-DNP-RNA |
| US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
| JP5122474B2 (ja) | 2005-12-01 | 2013-01-16 | プロネイ・セラピューティクス・インコーポレイテッド | 両性リポソーム製剤 |
| WO2007065017A2 (en) * | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Oligonucleotide cationic liposomal delivery system |
| US20090324587A1 (en) * | 2005-12-01 | 2009-12-31 | Neal Clifford Goodwin | Cancer Therapies and Pharmaceutical Compositions Used Therein |
| US20070270371A1 (en) * | 2006-03-31 | 2007-11-22 | Brown Bob D | Dosing and scheduling of oligomers |
| LT2735568T (lt) * | 2006-05-10 | 2017-11-27 | Sarepta Therapeutics, Inc. | Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų |
| US20100016215A1 (en) * | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CA2691673A1 (en) * | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
| US20110269665A1 (en) | 2009-06-26 | 2011-11-03 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
| CN101624596B (zh) * | 2009-08-12 | 2011-01-26 | 广州金琪基因技术研究发展中心 | 一种靶向c-myc癌基因的外指引序列 |
| KR101981705B1 (ko) | 2010-05-28 | 2019-05-24 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US9161948B2 (en) | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| KR20140097398A (ko) | 2011-11-18 | 2014-08-06 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| ITMI20120275A1 (it) * | 2012-02-24 | 2013-08-25 | Biogenera Societa A Responsabilita Limitata | Oligonucleotidi per la modulazione dell'espressione genica e loro usi |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| WO2016048054A2 (ko) * | 2014-09-24 | 2016-03-31 | 삼성전자 주식회사 | 데이터 통신 보안을 위한 방법, 장치 및 시스템 |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| NZ755416A (en) | 2016-12-19 | 2023-05-26 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
| CN108338986B (zh) * | 2017-01-23 | 2020-04-03 | 深圳开悦生命科技有限公司 | 一种用于治疗癌症的小分子rna及其应用 |
| WO2019165183A1 (en) | 2018-02-22 | 2019-08-29 | Entrada Therapeutics, Inc. | Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy |
| WO2019217682A1 (en) | 2018-05-09 | 2019-11-14 | Ohio State Innovation Foundation | Cyclic cell-penetrating peptides with one or more hydrophobic residues |
| CA3107890A1 (en) * | 2018-08-21 | 2020-02-27 | Deep Genomics Incorporated | Therapeutic splice-switching oligonucleotides |
| US20220088031A1 (en) * | 2019-02-01 | 2022-03-24 | Health Research, Inc. | Methods and compositions for treating resistant and recurrent forms of cancer |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| US12338437B2 (en) | 2020-05-11 | 2025-06-24 | Stoke Therapeutics, Inc. | OPA1 antisense oligomers for treatment of conditions and diseases |
| US12378267B2 (en) | 2021-06-17 | 2025-08-05 | Entrada Therapeutics, Inc. | Synthesis of FMOC-protected morpholino monomers and oligomers |
| US20250289851A1 (en) | 2022-04-22 | 2025-09-18 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| CN121194802A (zh) * | 2023-02-14 | 2025-12-23 | 斯托克制药公司 | 反义寡聚物调配物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4515781A (en) * | 1983-02-23 | 1985-05-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | 2',5'-Riboadenylate-morpholinoadenylate nucleotides |
| US6544755B1 (en) * | 1992-08-26 | 2003-04-08 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of diseases by expression of the c-Myc gene |
| BR9405707A (pt) * | 1993-01-07 | 1996-08-06 | Univ Jefferson | Inibiçao anti-sentido de c-myc para modular a proliferaçao de células de músculo liso |
| CA2250923A1 (en) * | 1996-03-26 | 1997-10-02 | Gabriella Zupi | Oligonucleotide treatments and compositions for human melanoma |
| AU5752601A (en) * | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
-
2002
- 2002-05-17 US US10/151,008 patent/US20030087861A1/en not_active Abandoned
- 2002-05-17 WO PCT/US2002/015842 patent/WO2002092617A1/en not_active Ceased
- 2002-05-17 NZ NZ530101A patent/NZ530101A/en unknown
- 2002-05-17 EP EP02769769A patent/EP1399462A4/en not_active Withdrawn
- 2002-05-17 CN CNA028100719A patent/CN1509292A/zh active Pending
- 2002-05-17 JP JP2002589500A patent/JP2004537517A/ja active Pending
- 2002-05-17 KR KR10-2003-7014985A patent/KR20040004629A/ko not_active Ceased
- 2002-05-17 CA CA002447052A patent/CA2447052A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11466274B2 (en) | Modified gapmer oligonucleotides and methods of use | |
| JP2002540137A5 (enExample) | ||
| US5455233A (en) | Oligoribonucleoside and oligodeoxyribonucleoside boranophosphates | |
| JP2007511504A5 (enExample) | ||
| JP2008533191A5 (enExample) | ||
| JP2024532465A5 (enExample) | ||
| KR20010080098A (ko) | 만성 ｃ형 간염 환자에서 검출 가능한 ｈｃｖ-ｒｎａ를제거하기 위한 리바비린-인터페론 알파 복합 치료 방법 | |
| UA44253C2 (uk) | Похідні фосфономоноефірів нуклеїнових кислот та олігонуклеотидвмісні похідні фосфономоноефірів нуклеїнових кислот | |
| AU2011257980A1 (en) | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups | |
| CA2518115A1 (en) | Nucleotide phosphoramidates as anticancer agents | |
| EP0618923A1 (en) | Peptide nucleic acids and their effect on genetic material | |
| JP2008536807A5 (enExample) | ||
| JP2022540333A5 (enExample) | ||
| JP2025509438A5 (enExample) | ||
| JP2024532464A5 (enExample) | ||
| JP4789095B2 (ja) | ウイルムス腫瘍遺伝子（ｗｔ１）に対する発現阻害物質を含んで成る固形腫瘍治療剤 | |
| JP2004523478A5 (enExample) | ||
| JP2023548295A5 (enExample) | ||
| JP2002523496A5 (enExample) | ||
| JPH02160769A (ja) | 新規な２′―ハロメチリデン、２′―エテニリデン及び２′―エチニルアデノシン誘導体類 | |
| CA2486872A1 (en) | Nf-kb inhibitors and uses thereof | |
| EP3083650B1 (en) | Novel ferrocenyl compounds | |
| JP2006515854A5 (enExample) | ||
| JPH02218689A (ja) | アデノシン誘導体、その製法および用途 | |
| CN1278261A (zh) | 新型喜树碱衍生物 |